Vical (VICL) Stock Price, News & Analysis

Company Overview

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.68 to $3.15
• 52-Week Range: N/A
• Volume: 35,024 shs
• Average Volume: 1.44 million shs
• Market Capitalization: $21.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VICL Stock Analysis - Frequently Asked Questions

How were Vical's earnings last quarter?

Vical Incorporated (NASDAQ:VICL) issued its earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.17) EPS for the quarter, meeting analysts' consensus estimates of ($0.17). The biotechnology company earned $0.12 million during the quarter, compared to the consensus estimate of $0.04 million. Vical had a negative trailing twelve-month return on equity of 29.46% and a negative net margin of 1,002.10%.

What other stocks do shareholders of Vical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vical investors own include Caladrius Biosciences (CLBS), Catalyst Pharmaceuticals (CPRX), Inovio Pharmaceuticals (INO), Cytori Therapeutics (CYTX), Synergy Pharmaceuticals (SGYP), CTI BioPharma (CTIC) and Idera Pharmaceuticals (IDRA).

Company Calendar

• Last Earnings: 2/19/2019
• Today: 6/24/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:VICL
• CIK: 819050
• Web: www.vical.com
• Phone: 858-646-1100
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.25 million
• Net Margins: -1,002.10%
• Pretax Margin: N/A
• Return on Equity: -29.46%
• Return on Assets: -27.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 36.84
• Quick Ratio: 36.84

Sales & Book Value

• Annual Sales: $1.62 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.82 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 22,840,000
• Free Float: N/A
• Market Cap: $21.01 million
• Optionable: Not Optionable
• Beta: 0.32